N@N

DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced that results from prophylactic use of the Impella 2.5 in complex coronary interventions from the USpella multicenter registry have been published in the December issue of the Catheterization and Cardiovascular Interventions Journal.

"Real-World Use of the Impella 2.5 Circulatory Support System in Complex High- Risk Percutaneous Coronary Intervention: The USpella Registry"

The publication is titled aReal-World Use of the Impella 2.5 Circulatory Support System in Complex High- Risk Percutaneous Coronary Intervention: The USpella Registry,a and is authored by Brijeshwar Maini, MD, Srihari S. Naidu ,MD, Suresh Mulukutla, MD, Neal Kleiman, MD,Theodore Schreiber, MD, David Wohns, MD, Simon Dixon, MBChB, Charanjit Rihal, MD, Rajesh Dave, MD, and William OaNeill, MD.

The analysis demonstrated [ similar results seen in the PROTECT II study ], with an overall statistically significant improvement of left ventricular ejection fraction for patients receiving percutaneous revascularization with Impella support. Additionally, as in PROTECT II, there was a significant improvement of the functional heart failure status by one or more New York Heart Association (NYHA) classes. The final PROTECT II results were presented in a TCTMD webcast and can be viewed here at [ www.tctmd.com/mm.aspx ].

The Catheterization and Cardiovascular Interventions Journal paper can be accessed at: [ http://onlinelibrary.wiley.com/doi/10.1002/ccd.23403/abstract ].

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.